Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $58,839 | $43,876 | $39,681 | $10,000 |
| % Growth | 34.1% | 10.6% | 296.8% | – |
| Cost of Goods Sold | $45,238 | $42,587 | $48,275 | $0 |
| Gross Profit | $13,601 | $1,289 | -$8,594 | $10,000 |
| % Margin | 23.1% | 2.9% | -21.7% | 100% |
| R&D Expenses | $314,421 | $241,226 | $155,696 | $135,271 |
| G&A Expenses | $178,184 | $110,822 | $81,599 | $57,682 |
| SG&A Expenses | $178,184 | $110,822 | $81,599 | $57,682 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$699 | -$162 | -$178 |
| Operating Expenses | $492,605 | $351,349 | $237,133 | $192,775 |
| Operating Income | -$479,004 | -$350,060 | -$245,727 | -$182,775 |
| % Margin | -814.1% | -797.8% | -619.3% | -1,827.8% |
| Other Income/Exp. Net | $14,216 | $17,932 | $6,251 | -$3,704 |
| Pre-Tax Income | -$464,788 | -$332,128 | -$239,476 | -$186,479 |
| Tax Expense | -$1,127 | -$4,062 | $0 | $0 |
| Net Income | -$463,661 | -$328,066 | -$239,476 | -$186,479 |
| % Margin | -788% | -747.7% | -603.5% | -1,864.8% |
| EPS | -1.69 | -1.58 | -1.36 | -1.05 |
| % Growth | -7% | -16.2% | -29.5% | – |
| EPS Diluted | -1.69 | -1.58 | -1.36 | -1.05 |
| Weighted Avg Shares Out | 274,207 | 207,854 | 175,537 | 170,272 |
| Weighted Avg Shares Out Dil | 274,207 | 207,854 | 175,537 | 170,272 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,758 | $19,116 | $6,254 | $73 |
| Interest Expense | $1,572 | $97 | $55 | $2,952 |
| Depreciation & Amortization | $36,494 | $24,402 | $11,756 | $8,405 |
| EBITDA | -$426,722 | -$307,629 | -$227,665 | -$175,122 |
| % Margin | -725.2% | -701.1% | -573.7% | -1,751.2% |